Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is rare with a poor outcome and is resistant to conventional cytotoxic chemotherapy. The efficacy and safety of durvalumab and tremelimumab for treating recurrent or metastatic PSCs were assessed by a nonrandomized, open‐label, phase II study. METHOD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Kim, Miso, Keam, Bhumsuk, Ock, Chan‐Young, Kim, Se Hyun, Kim, Yu Jung, Lim, Sun Min, Kim, Jin‐Soo, Kim, Tae Min, Hong, Sook‐Hee, Ahn, Mi Sun, Shin, Seong Hoon, Kang, Eun Joo, Kim, Dong‐Wan, Im, Sun‐Wha, Kim, Jong‐Il, Lee, Jong Seok, Kim, Joo‐Hang, Heo, Dae Seog
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7705626/
https://ncbi.nlm.nih.gov/pubmed/33026712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13684
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados